Issue link: https://www.e-digitaleditions.com/i/1544305
Inhalation April 2026 31 amount to useful results, but instrument operation is often different than in other fields. For example, pharmaceutical materials are often low Z materials and require low X-ray energies to maximize contrast, whereas many material science or geological samples require higher voltages for sufficient transmission. Finally, there is the challenge of data interpretation. Often XCT of pharmaceutical materials contain a combination of absorption contrast and phase con- trast. Naive interpretation may assign the bright peak in a phase fringe to be a highly dense material, whereas it simply marks the boundary of one partic- ular material. erefore, along with technical barri- ers, there can be limited results showing utility. Often when exploring XCT techniques, pharmaceutical scientists question firstly whether it will be effective with their samples, and secondly, whether it can add value to their project. Consequently, XCT has not penetrated deep into the pharmaceutical industry, Navigating a complex landscape Despite the considerable potential for X-ray com- puted tomography to complement other techniques with its non-destructive and 3D attributes, the XCT landscape is very complex, with a large technical barrier. Pharmaceutical materials provide very dif- ferent challenges than other fields such as material science or geology where XCT is prevalent. Firstly, there is the challenge of sample preparation. In many cases, especially for nanoscale XCT, focused- ion-beam (FIB) milling is used to prepare material science samples, however, such preparation is too aggressive for pharmaceutical samples such as tab- lets and is completely unsuitable for powder sam- ples or situations where non-destructive analysis is desired. Even direct use of glue to secure pharmaceu- tical compounds may react with the organic com- pounds present. Secondly, there is the challenge of instrument operation. Obtaining good data is par- Figure 3 Visualization of different formulated blends, comprised for Lactohale 100 (LH100) blended with (A) Lactohale 300 (LH300); (B) Micronized terbutaline sulphate (micTBS); (C) Micronized fluticasone propionate (micFP). Figure adapted with permission from [6]. C B A 100 µm LH300 Blend 100 µm micTBS Blend 100 µm micFP Blend Figure 4 (A, B) 3D visualization from XCT of two particle structures formed in the blend of lactose monohydrate with micronized fluticasone propionate; (C) 2D-visualization of the same blend using SEM imaging. Adapted with permission from [18]. A B C 10 µm Thickness (µm) 0 - 10 20 µm Thickness (µm) 0 - 10 10 kV X350 50 µm

